Literature DB >> 19415419

Headache induced by the use of combined oral contraceptives.

Gianni Allais1, Ilaria Castagnoli Gabellari, Gisella Airola, Paola Borgogno, Paola Schiapparelli, Chiara Benedetto.   

Abstract

Although combined oral contraceptives (COCs) are a safe and highly effective method of birth control, they may also give rise to problems of clinical tolerability in migraine patients. Indeed, headache is among the most common side effects reported with the use of COCs, frequently leading to their being discontinued. The latest International Classification of Headache Disorders identified at least two entities evidently related to the use of COCs, i.e., exogenous hormone-induced headache and estrogen-withdrawal headache. As to the former, the newest formulations of COCs are generally well tolerated by migraine without aura patients, but can worsen headache in migraine with aura patients. Headache associated with COCs, generally, tends to improve as their use continues. However, although it is not yet clear if there is an association between headache and the composition of COCs (both in the type and amount of hormones), it has been observed that the incidence of headache during COC use seems greater if migraine is associated with menstrual trigger. The estrogen-withdrawal headache is a headache that generally appears within the first 5 days after cessation of estrogen use and resolves within 3 days, even if in some cases it may appear on the sixth or seventh day after pill suspension and lasts more than 3 days.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415419     DOI: 10.1007/s10072-009-0051-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  3 in total

1.  Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days.

Authors:  Gabriele S Merki-Feld; Bruno Imthurn; Ronald Langner; Burkhardt Seifert; Andreas R Gantenbein
Journal:  J Headache Pain       Date:  2015-05-01       Impact factor: 7.277

2.  Frovatriptan vs. other triptans for the acute treatment of oral contraceptive-induced menstrual migraine: pooled analysis of three double-blind, randomized, crossover, multicenter studies.

Authors:  G Allais; V Tullo; S Omboni; D Pezzola; D Zava; C Benedetto; G Bussone
Journal:  Neurol Sci       Date:  2013-05       Impact factor: 3.307

3.  A Survey on Migraine Prevalence in Patients with Inflammatory Bowel Disease - A Single Centre Experience.

Authors:  Somaye Chehel Cheraghi; Nasser Ebrahimi Daryani; Mojdeh Ghabaee
Journal:  Middle East J Dig Dis       Date:  2016-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.